Company news
Oncolytics Biotech Inc. news in 2020
Oncolytics Biotech Inc.'s news releases, calls and decks from 2020, newest first.
Oncolytics and SOLTI Report Clinical Synergy of Pelareorep with Checkpoint Inhibitors at the 2020 San Antonio Breast Cancer Symposium
December 9, 2020
Oncolytics Biotech® Announces Positive Clinical Results Against Glioblastoma Multiforme at the 2020 Society of Neuro-Oncology Annual Meeting
November 19, 2020
Oncolytics Biotech® to Present AWARE-1 Data and Provide Updates on Phase 2 BRACELET-1 and IRENE Trials at the 2020 San Antonio Breast Cancer Symposium
November 17, 2020
Oncolytics Biotech® Reports 2020 Third Quarter Development Highlights and Financial Results
November 11, 2020
Oncolytics Biotech® and SOLTI Present Clinical Breast Cancer Data Highlighting Pelareorep-Induced Anti-Tumor T Cell Responses at The Society for Immunotherapy of Cancer Annual Meeting
November 9, 2020
Oncolytics Biotech® Announces Abstract Publication and Upcoming Oral Presentation at the 2020 Society of Neuro-Oncology Annual Meeting
November 9, 2020
Oncolytics Biotech® Collaborates with Roche and AIO to Initiate a Phase 1/2 Gastrointestinal Cancer Trial Combining Pelareorep with Roche's Anti-PD-L1 Checkpoint Inhibitor
October 27, 2020
Oncolytics Biotech® Appoints Richard Vile, Ph.D., to its Scientific Advisory Board
October 19, 2020
Oncolytics Biotech® to Participate in BIO Investor Forum Digital
October 7, 2020
Oncolytics Biotech® Announces Upcoming Presentations at Investor Conferences
September 1, 2020
Oncolytics Biotech® Doses First Patient in Phase 2 IRENE Study Evaluating Pelareorep-anti-PD-1 Combination Treatment in Triple-Negative Breast Cancer
August 26, 2020
Oncolytics Biotech® to Participate in Virtual Fireside Chat at the Canaccord Genuity 40th Annual Growth Conference
August 10, 2020
Oncolytics Biotech® Reports 2020 Second Quarter Financial Results and Operational Highlights
August 4, 2020
Oncolytics Biotech® Announces Investigator Sponsored Phase 2 Trial Evaluating Pelareorep-anti-PD-1 Combination Treatment in Triple-Negative Breast Cancer
June 25, 2020
Oncolytics Biotech® Doses First Patient in Phase 2 BRACELET-1 Study Evaluating Pelareorep-Based Combination Therapies in Metastatic Breast Cancer
June 23, 2020
Oncolytics Biotech® Provides Recap of Key Opinion Leader Call Highlighting the Induction of Rapid and Persistent Immune Responses With Systemic Pelareorep Treatment
June 4, 2020
Oncolytics Biotech® Presents Clinical Proof-of-Concept Data in Multiple Myeloma at the ASCO Virtual Annual Meeting
May 29, 2020
Oncolytics Biotech® Presents Clinical Data Supporting a Predictive Biomarker of Pelareorep Response in Breast Cancer at the ESMO Breast Cancer Virtual Meeting
May 26, 2020
Oncolytics Biotech® Announces Publication of Abstracts at the 2020 American Society of Clinical Oncology Virtual Annual Meeting
May 14, 2020
Oncolytics Biotech® to Present at the RBC Global Healthcare Conference
May 13, 2020
Oncolytics Biotech® Reports 2020 First Quarter Financial Results and Operational Highlights
May 8, 2020
Oncolytics Biotech® to Present Clinical Findings of Pelareorep-Induced Immune Response in Breast Tumors at the ESMO Breast Cancer Virtual Meeting
May 4, 2020
Oncolytics Biotech® Announces Changes to Annual General Meeting
April 30, 2020
Oncolytics Biotech® Updates Clinical Development and Operations Activities During the COVID-19 Pandemic
April 17, 2020
Oncolytics Biotech® Announces Publication of Pelareorep's Clinical Benefit Against KRAS Mutated Colorectal Cancer
April 2, 2020
Oncolytics Biotech® Announces Favourable AWARE-1 Safety Update
March 24, 2020
Oncolytics Biotech® Reports Fourth Quarter and Full Year 2019 Financial Results and Operational Highlights
March 5, 2020
Oncolytics Biotech® to Host Conference Call to Discuss Fourth Quarter and Year End 2019 Financial Results and Operational Highlights
February 28, 2020
Oncolytics Biotech® Provides Recap of Key Opinion Leader Call Highlighting Pelareorep's Unique Ability to Activate the Immune System in Late Stage Multiple Myeloma
January 13, 2020
Oncolytics Biotech® Announces Key Opinion Leader Call Conducted by ROTH Capital Partners to Discuss Multiple Myeloma
January 9, 2020